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The development of unsta le angina is most corn 
comitant platelet acti 
thrombus formation (I-3). Consequently, seemingly ogical 
treatment s rategies have evolved for the management of 
patients with unstable angina. There is compelling evidence 
from several large-scale trials that aspirin is beneficial in 
treating unstable angina (4-7). In contrast, placebo- 
controlled trials of heparin therapy have produced iscor- 
dant results (6-g). Nonetheless, patients frequently receive 
both aspirin and heparin during the acute phase of unstable 
angina despite the lack of evidence from clinical trials that 
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The role of aspirin in the management of unstable angina 
is well established; thus, the real clinical question is not 
whether heparin is the same or better than aspirin, but 
whether combination therapy with heparin and aspirin ccm- 
fers any advantage to the patient over aspirin therapy alone. 
Because continuing myocardial ischemia identifies those 
patients with unstable angina who are at greater risk for 
subsequent c iac events (9-11). we have addressed 
issue by dete ning the effect of 
heparin and aspirin versus aspirin 
myocardial ischemia sad in-hospital prognosis. 
Consecutive patients with a clinical diagnosis ofunst 
angina who fulfilled the entry criteria entered a single-blind, 
07351097/941$7.00 
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randomized multicenter trial comparing the effects of bepa- 
r-in and aspirin versus aspirin alone on transient myocardial 
&hernia and in-hospital prognosis. Patients were recruited 
between October 1 and October 1992 from three district 
general hospitals in the United Kingdom (Royal United 
Hospital, Bath; Hillingdon Hospital, Uxbridge; Wycomk 
General Hospital, High Wycombe). All data were analyzed 
centrally at the Royal Brompton National Heart and Lung 
based on history of chest 
nal chest pain < 1 month 
tion, the recent development of more readily provoked 
v rest or nocturnal chest 
ischemia and angina 
ial infarction (12). The 
ad to have occurred within 
rmed consent. The exclusion criteria were evidence of 
an evolving Q wave myocardial infarction on the admission 
electrocardiogram (ECG), clinical contraindications to hep 
arin or aspirin administration, concomitant therapy with 
watfarin or other anticoagulants, thrombocytopenia (pl telet 
count <lo0 x 10’2/liter), pregnancy, diabetic proliferative 
retinopathy and ECG changes making interpretation f ST 
segment recordings impossible (complete l ft bundle branch 
block, left ventricular hypertrophy and changes associated 
with digoxin administration). The demonstration of revers- 
ible ST segment shift was not an entry criterion. lnforme 
written consent was obtained from all patients entering the 
trial, in accordance with guide1 es established bythe ethical 
committees of all participati centers that approved the 
study. 
py. Patients were admitted to the coronary 
and placed on strict bed rest for at least 48 h. Drug 
therapy was initiated immediately when the patient entered 
the trial. Unless contraindicated, pirtients received an intra- 
venous infusion of nitrates for ~48 h at the minimal dose 
required to render them pain free, oral beta-adrenergic 
ts to maintain a rest heart rate ~70 beats/min 
68 mg orally three times a day. Beta-blocker 
and diltiazem therapy was continued throughout the hospital 
admission. Patients were randomized to receive ither hep- 
arin and aspirin (150 mg orally once daily) (Group H + A) or 
aspirin alone (150 mg orally once daily) (Group A). Heparin 
was administered as an intravenous bolus of 5,080 U sodium 
heparin, followed immediately b a continuous infusion to 
maintain the activated partial thromboplastin time between 
1.5 and 2.5 X baseline. The activated partial thromboplastin 
time was measured 4 to 6 h after initiating therapy and daily 
thereafter, and the dose of heparin was adjusted accordingly. 
The intended uration of heparin infusion was 48 h. 
Additional b tests. A full blood count and cardiac 
enzyme levels were measured on entry into the trial and 
daily thereafter for at least 48 
condition had not st 
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, or longer if the patie 
was kept for all patie 
ent rn~~ito~i~g to record 
pam. 
ing on the patient’s ymptoms recorded on the chest pain 
chart at that time. The results of ST segment monitoring 
were not disclosed to the attending physician. 
ion of terms. The trial was designed 
heparin and aspirin versus aspirin 
alone on transient myocardial schemia and the development 
of myocardial infarction or death in hospital. Comparisons 
were made between the number of patients ineach treatment 
group with episodes of transient myocardial ischemia, total 
number of episodes and total duration of ischemia. The 
incidence ofdeath, myocardial nfarction (fatal and nonfatal) 
and combined myocardial infarction or death in hospital 
were determined for both treatment groups, for patients wit 
and without ransient myocardial ischemia (irrespective of 
treatment) and for patients according to treatment and the 
presence orabsence oftransient myocardial ischemia. Myo- 
cardial infarction was defined as twofold or greater increase 
in cardiac enzyme levels in association with either severe 
chest pain of long duration or ECG changes characteristic of 
myocardial nfarction (development of pathologic Q waves, 
loss of R wave amplitude, ST segment elevation with sub- 
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1 
admission. 
The two groups were simi 
factors for coronary art 
ial ~~farct~o~ and t 
admission EGG in more than 
-t A vs. 72.5% in 
se, similar combers 
NS). In the remaining patients, these drugs were either not 
begun or were withdrawn because of hypotension rbrady- 
cardia. Fifteen patients ( ix in Group H t A, nine in Group 
A) did not receive or could not tolerate aspirin because of 
gastric erosions, peptic ulceration or aspirin 
eparin therapy was started promptly after admis- 
sion (mean 4.6 + 1.2 h) and continued for 46.1 C 1.1 h. The 
activated partial thromboF~astin time on admission was 42 + 
I s and increased to101 c 4 s with heparin administration. 
One patient in Group I-T + A had a hematemesis after 20 h of 
heparin therapy (activated partial thromboplastin time 69 s) 
that required blood transfusion. One patient in Group A 
developed a rectus heath ematoma that required surgical 
Female (%) 19.5 19.9 
58.3 ? 0.8” .6 + 0.8 
51 (33%) 31 (24%) 
Former smoker 77 (50%) 67 (51%) 
48 (31%) 48 (37%) 
13 (8%) 6 (5%) 
88 (57%) 73 (56%) 
81 (53%) 74 (57%) 
46 r 7 48 2 8 
62 (40%) 51 (39%) 
edication on admission 
Beta-blocker 52 (34%) 48 (37%) 
44 (29%) 41 (31%) 
51 (33%) 47 (36%) 
31(24%) 33 (25%) 
52 (34%) 48 (37%) 
Diuretic 26 (17%) 25 (1%) 
ACE inhibitor 8 (5%) IO (8%) 
Cardiac enzymes >2 X U&N on admission 10 (7%) l5 (I 1%) 
“p = 0.04 versus Group A. Data presented are mean values 51 SEM or 
number (%I of patients. Gro = aspirin alone; Group N + A = combined 
heparin and aspirin therapy; = ischemic heart disease: MP = myocardial 
infarction; po = oral; sl = sublingual; td = transdermal; ULN = upper limit 
of normal. 
evacuation u der general nest 
re were one or 
duration of ischemia in 
H t A vs. 4,908 min in 
Group A contributed a total of 1,360 min of transient 
ischemia, inwhich one episode lasted 1,062 min. Consider- 
ing those patients wit odes of transient my 
ischemia, 14 (52%, Group t A) and I.8 (58%, G 
patients had a total of 2 min of ischemia (p = 0.83, Group 
H t A vs. Group A). The Froportion of episodes with ST 
segment elevation was similar in both groups, as was the 
proportion ofsilent and painful episodes. 
Analysis of the two treatment groups 
patients with a significant increase incard 
on admission (Group 
patients) with regard to the number of e 
transient myocardial ischemia and total i
ces between the two groups. 
s. Myocardial infarction and death. 
Event-free survival from myocardial infarction or death was 
similar in both treatment groups (Fig. 1) and was unaffected 
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Tape Variables 
Total duration of ST segmen! moni!oriag !h! 
Duration/pt (h) 
No. of pts (I) with rl episode of TM1 
Total no. of episodes 
rbMarL& 
Range/pt 
Median episode duration (min) 
Range 0nin) 
Total duration of &hernia (min) 
Episodes of ST segment elevation 
Silenl episodes 
Pts with >60 min TM1 
AU Patients 
I I.622 
40.9 + 0.7 
58 (20%) 
244 
0 
O-23 
15.0 
l-l ,062 
7.819 
72 (30%) 
190 (82%) 
32158 (SS%) 
Group H t A 
6,114 
39.7 + 1.0 
27 (18%) 
% 
0 
O-12 
13.5 
2.911 
29 (3l-W 
76 (19%) 
14127 Wxl) 
grout A 
5,508 
42.2 + 0.9 
31 (24%) 
148 
0 
O-23 
16.0 
18131 (58%) 
Data presented are mean values + SEM or number (96) of patients (pt, pts, Pts). TMI = trnnsicnt myocsrdial 
isehemia; other abbreviations as in Table I. 
e of ~reseatatioo. The incidence of myocard~~ 
infarction or death (Table 3) was 53% in patients with a 
positive tape compared with 22% in patients with a negative 
We(p<O. 1). Five of the six deaths occurred in patients 
with transient myocardial ischemia. Although event-free 
survival from myocardial infarction or death was signifi- 
cantly lower in patients with episodes of transient myocar- 
dial ischemia compared with patients without (Fig. 21, there 
was no difference between the two treatment groups in this 
respect (Fig. 3). Among patients with episodes of transient 
myocardial ischemia, events were no more f~eqMe~t i 
patients with 260 min of total ischemia compared wit 
patients with ~60 min of total ischemia. 
Cardiac catheterization and rev~~(~M~arjzQtion. Similar 
numbers ofpatients inthe t 
cardiac atheterization (31[ 
in Group A) or revascuhuization by either angioplasty or
coronary artery bypass urgery (19 [12%] in Grectp W t A, 
1. Event-free survival from myocardial 
ing to treatment. S&J line = aspirin al 
combined heparin and aspirin therapy. 
th 
= 
0.41 
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 
Time (days) 
atients with than 
In the entire cohort of 285 
patients, 34 indecent ascMla~~tioa (17% of patients 
with transient myocardi~ ischemia, 11% of patients without) 
by either percutaneous coronary angiop~as~y or coronary 
artery bypass urgery during their hospital admission. 
E$ect of preadmission therapy. The incidence of myo- 
cardial infarction (fatal and nonfatal) was assessed in the 
entire study group according to preadmission therapy with 
beta-blockers, calcium antagonists and aspirin. The inci- 
dence of myocardial infarction was unaffected by preadmis- 
sion therapy with beta-blockers or calcium antagonists but 
was lower in patients admitted taking aspirin compared with 
patients not previously taking aspirin (19% vs. 34%, respec- 
CC. Episodes of tran- 
only 2 patients (3.1%) 
with a normal ECG on admission, compared with 56 
(22.7%) with abnormalities on the admission ECG (p < 
O.OOOl). Events were infrequent in patients with a normal 
admission ECG (eight myocardial infarctions, fotir revascu- 
larization procedures, rm deatbs~. In contrast, here were 73 
myocardial nfarctions (p= 0.0001 vs. patients with a normal 
admission ECG) and 30 revascularization procedures in
patients with an abnormal ECG on admission; all the deaths 
occurred in this group. 
(53%) (59%) (48%) 
511227 261127 2511 
(22%F (20%)? (25%)$ 
Cardiac ~at~ele~~~ti~~ (n = 54) + 17158 8127 9131 
(29%) (30%) (29%) 
371227 231127 141100 
(16%)8 (18%) (14%) 
f 10158 6l27 4131 
(17%) (22%) (13%) 
241227 131127 1111 
(II%) (10%) (II%) 
*$I < 0. I versus all patients with transient myoclrr 1). tp <: 0.0001 versus Group 
patients wit nsienl l~y~i~r~i~~ iscbemia. $p = 0.01 versus Cr0 trrnsient myocardinl ischemia. 
Ip = 0.04 versus all pstients with transient ata presented are number (%) of patients. 
CABG = coronary artery bypass graft surgery. t~a~s~M~~~a~ coronary angioplasty: t (-) = 
presence (absence) of transient myocardial ischemia: other abbreviations as in Table 1. 
a sig~jficaRt risk of myocardia~ ~~~arct~o~ and death. Hn the 
plaque in a coronary arter 
plete occlusion of the coronary artery is associated with the 
Figure 2. Event-free survival from myocardial infarction or death 
according to the presence ( line) or absence (soli 
transient myocardial ischemia. 
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0.9 - 
R 0.8 - 
i 
: 
: 
‘- I 
: 
p=0.0001 
I_.._- 
I ______ 
:_____________________________ 
0.4’ i I 1 / ’ i 
1 
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 
Time (days) 
~~g~~e 3. Event-free survival from myocardial infarction or death 
according to treatment and the presence or absence of transient 
myocardial ischemia. S lines = aspirin alone; ked Pines = 
combined heparin and top lines absence of 
transient myocardial ischemia es = presence of transient 
myocardial ischemia. 
0.6 
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from 75 mg once daily (7) to 325 mg four times aday 1% have 
demonstrated a reduction in risk of nonfaial myocardial 
infarction and death >50%. 
py. In contrast to the aspirin 
studies, the results that have emerged from trials of heparin 
therapy have been less concordant, The first randomized 
placebo-controlled study of heparin therapy in unstable 
angina reported a significant reduction i  the incidence of 
myocardiai infarction with heparin administration (8. The 
second placebo-controlled trialof heparin therapy compared 
aspirin versus heparin versus aspirin aud heparin (6). The 
incidence of fatal or nonfatal myocardial infarction was 
reduced significantly in all three treatment arms compared 
with placebo therapy. More recently, the Besearch Group on 
Instability in Coronary Artery ase (RISC) group (7) 
compared aspirin versus heparin us aspirin and he~~~~ 
in unstable coronary artery disease. In contrast o the 
previous tudy (4), the incidence of myocardial infarct~~a 
and death in the heparin group was the same as in the 
placebo group, However, treatment with aspirin was effec- 
tive, whether given as monotherapy or in combination with 
heparin. Possible reasons for the apparent lack of effect of 
heparin include a delay in the initiation of heparin therapy 
(median delay 33 h) and the use of intermittent i ravenous 
heparin rather than a continuous infusion. In view of the 
uncertainty with regard to the effect of intermittent heparin 
therapy (7), we chose to give heparin as a continuous 
infusion. 
Because aspirin is an established treatment in unstable 
angina, the most pertinent clinical question to be answered is 
whether combination therapy is better than treatment with 
aspirin alone. We were unable to demonstrate ny superior- 
ity with combination therapy compared with aspirin alone. 
In the RISC study combination therapy was the only treat- 
ment superior to placebo therapy at 5 days (p = 0.03). 
although it was not significantly different from aspirin treat- 
ment alone. Beyond 5 days the aspirin and combined treat- 
ment arms merged. No significant differences between the 
three treatment arms with respect to fatal or nonfatal myo- 
cardial infarction were demonstrated by Theroux et al. (6). 
Taken together, these results suggest that there is no advan- 
from combination thera pared with as 
on transient 
lschemia is assocta 
an increased event rate in patients with unstable angina 
(9-11). We believe that our study is the first reported 
comparison f the effects of combined therapy versus aspirin 
On transient myocardial ischemia. Other investigators have 
examined the effects of treatment on the incidence ofrefrac- 
tory angina (6). which is a more subjective end point and is 
not interchangeable with transient ischemia. Indeed, the vast 
majority of episodes of transient ischemia re silent (9,tO) 
and are therefore unlikely to be detected clinically without 
the benefit of continuous ECG monitoring. 
One earlier study compared the effects of monotherapy with 
heparin, aspirin and alteplase ontransient myocardia) ischemia 
most effective ~atme~t. 
believe that our rest&s bear 
stab/e angina is an ~rnbre~~a 
ally would not receive thromholysis n the absence of 
evolving myoc~dial infarction. 
The incidence of myocardia! infarction was higher in our 
study compared with other eports (4-7.16). The myocardial 
infarction rate will depend to an extent on the definition of 
unstable angina because non-Q wave myocardial infarction 
is sometimes included in the definition. Over 50% of the 
myocardial nfarcts in our study were not associated with the 
development of pathologic Q waves, which probably ac- 
counts for the higher infarction rate in our study. Addition- 
ally, 25 patients had a significant increase incardiac enzyme 
levels on admission but were recruited on an intention-to- 
treat basis. We elected not to use the results of cardiac 
enzymes as a criterion for inclusion or exclusion because 
these results were not available at the time of admission to
hospital. Instead, we decided apriori to perform asubgroup 
analysis after exclusion of such patients. 
The results of our study should not be extrapolated to the 
use of heparin as monotherapy in unstable angina. A~thoMgh 
we did not assess heparin therapy in isolation, there is 
evidence that continuous intravenous heparin is as effective 
as aspirin in preventing myocardial nfarction (6). Therefore, 
patients in whom aspirin is c~~t~i~dicated may be candi- 
dates for heparin therapy. However, arebound phenomenon 
has been observed shortly after discontinuation f heparin 
that appears to be prevented by the coadministration of 
aspirin (17). 
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